Skip to main content
. 2020 Jan 16;28(1):159–169. doi: 10.1007/s40199-020-00326-z

Fig. 4.

Fig. 4

Assessment of HMGB1 and HSP70 release by ELISA following treatment with (a) DOX, stattic and DOX + stattic in B16F10, (b) DOX, stattic and DOX + stattic and (c) OXP, stattic and OXP + stattic in CT26 cells. The experiments were repeated in triplicate and data are indicated as the mean ± SD. DOX, doxorubicin; OXP; oxaliplatin, ns; not significant